{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-000150","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.960849+00:00","generated_at":"2026-06-07T01:24:08.496744+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products","bullets":["Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.","Initial 2-year term auto-renewing; royalty on Net Sales (percentage redacted) due quarterly.","Marketing through Sonoma's existing EU distribution network; NovaBay retains rights outside territories.","NovaBay represents it owns the marks, but applications in EU are still pending as previously disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-000150","json":"https://secwatch.observer/filing/0001683168-24-000150.json","markdown":"https://secwatch.observer/filing/0001683168-24-000150.md","text":"https://secwatch.observer/filing/0001683168-24-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/0001683168-24-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:24:08.496744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17ff760772cede39462346b29151e48364d5a48b","claim":"Sonoma Pharmaceuticals, Inc. entered into a license with NovaBay Pharmaceuticals, Inc. (effective 2024-01-05).","evidence_excerpt":"Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova ® -branded products by the Company in the European Union.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/0001683168-24-000150-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"NovaBay Pharmaceuticals, Inc."},{"label":"Effective","value":"2024-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}